IL-27 alleviates high-fat diet-induced obesity and metabolic disorders by inhibiting adipogenesis via activating HDAC6
March 19, 2025 / IL-27 Obesity Therapy / Metabolic disorder Treatment / HDAC6 Activation
Interleukin-27 (IL-27) inhibits adipogenesis and improves metabolic health in high-fat diet-induced obesity by activating HDAC6 and the TGFβ/Smad3 pathway. In vivo and in vitro findings suggest IL-27 as a potential therapeutic target for obesity and metabolic disorders.
The Natural Molecule That Could Rival Ozempic
March 18, 2025 / Natural Weight Loss Peptide / BRP Obesity Treatment / GLP-1 Alternative / Metabolic Health / Peptide Therapy
Stanford researchers identified BRINP2-related peptide (BRP), a non-incretin hormone, as a potential natural weight loss treatment. Unlike GLP-1 receptor agonists like Ozempic, BRP may offer metabolic benefits with fewer side effects, providing an alternative for obesity management.”
Risk of longer-term endocrine and metabolic conditions in the Deepwater Horizon Oil Spill Coast Guard cohort study – five years of follow-up
March 22, 2025 / Deepwater Horizon Health Effects / Oil Spill Endocrine Disruption / Metabolic Disorders / Coast Guard Health Study
The Deepwater Horizon Oil Spill responders showed increased risks of metabolic and endocrine disorders, including hyperlipidemia, obesity, and thyroid dysfunction, five years post-exposure. Risks were higher in those exposed to both crude oil and dispersants, highlighting potential long-term health effects.
Opko and Entera focus on oral care for obesity and metabolic disorders
March 18, 2025 / Opka Health / Entera Bio / Oral GLP-1 Therapy / Obesity Treatment / Metabolic Disorders
Opko Health and Entera Bio are collaborating to develop the first oral GLP-1/glucagon dual agonist for obesity and metabolic disorders. Their program, leveraging Opko’s oxyntomodulin analog and Entera’s N-Tab technology, aims to advance into clinical trials in 2025.
TIFR study proposes potential therapeutic to mitigate metabolic effects of sugary beverages
March 21, 2024 / TIFR Study / Sugar-sweetened Beverages / Metabolic Disorders / Obesity Diabetes / Glucose Metabolism / Therapeutic Targets
A TIFR study links chronic sugar-sweetened beverage (SSB) consumption to metabolic disorders like obesity and diabetes. Findings suggest intestinal glucose absorption disrupts metabolism, exacerbating organ dysfunction. Researchers propose targeting nutrient transport and mitochondrial function as potential therapeutic strategies.
Diet affects the brain’s insulin sensitivity, promoting obesity
March 20, 2025 / Brain Insulin Sensitivity / Obesity Risk / Type 2 Diabetes / Processed Foods / Metabolic Disorders
A study shows that short-term consumption of highly processed foods reduces brain insulin sensitivity, promoting obesity and metabolic disorders. Even after resuming a normal diet, insulin resistance in the brain persists, potentially triggering obesity and type 2 diabetes.
Chronic jet lag disrupts metabolism differently in male and female mice, study finds
March 20, 2025 / Jet Lag Metabolism / Gender Differences / Glucose Intolerance / Shift Work Health Risks
A study on mice found that chronic jet lag disrupts metabolism differently by sex—males gained weight and developed glucose intolerance, while females lost weight. Testosterone plays a role in metabolic resilience, highlighting the need for gender-specific health strategies for shift workers.
Hormel Institute makes discovery about cell metabolism
March 17, 2025 / Cell Metabolism / Gene Isoforms / Metabolic Regulation / RNA Therapy / Obesity Treatment
Researchers at The Hormel Institute discovered that cells regulate metabolism by using alternative gene isoforms in response to nutrient availability. This process plays a crucial role in metabolic health, with implications for developing RNA-based therapies for obesity and diabetes.
New Study Links Nutrition To Mortality Risk In Metabolic Syndrome
March 22, 2025 / Cardiometabolic Syndrome / Inflammation / Nutrition Mortality / Advanced Lung Cancer Inflammation Index / Cardiovascular Risk
A study in Scientific Reports links nutrition and inflammation to mortality risk in cardiometabolic syndrome (CMS). Using NHANES data, researchers found that the Advanced Lung Cancer Inflammation Index (ALI) predicts all-cause and cardiovascular mortality, highlighting the need for nutritional interventions.
Eli Lilly Introduces Mounjaro in India: Much Needed Breakthrough in Obesity and Diabetes Management
March 22, 2024 / Mounjaro India Launch / Trizepatide Diabetes Treatment / Obesity Management / GLP-1 Receptor Agonist / Eli Lilly
Eli Lilly has launched Mounjaro (tirzepatide) in India for obesity and type 2 diabetes management. The dual GIP/GLP-1 receptor agonist enhances weight loss and glycemic control, offering a novel, once-weekly injectable therapy for patients with metabolic disorders.
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development
March 21, 2025 / MetaVia Cardiometabolic Drugs / Obesity Treatment / MASH Therapy / Clinical Trial Updates / Biotech Investments
MetaVia Inc. (formerly NeuroBo) is advancing DA-1726 and DA-1241 for obesity and MASH treatment. Positive Phase 2a results for DA-1241 were reported, with Phase 1 data for DA-1726 expected in April 2025. Clinical expansion and financial investments continue.
What is Metabolic-associated Fatty Liver Disease? Risks, tips to avoid ‘silent epidemic’
March 21, 2025 / Metabolic Fatty Liver Disease / MAFLD Risk Factors / Fatty Liver Preventions / Obesity / Liver Health
Metabolic-associated Fatty Liver Disease (MAFLD), formerly NAFLD, is a growing public health concern linked to obesity, high cholesterol, and sedentary lifestyles. Experts emphasize prevention through dietary changes and active living to reduce liver fat accumulation and metabolic risks.
High-Intensity Interval Training Enhances Glycemic Control and Cardiometabolic Health in Type 2 Diabetes: Study Finds “
March 19, 2025 / HIIT / Type 2 Diabetes / Glycemic Control Exercise / Cardiometabolic Health / Diabetes Fitness
A meta-analysis of 76 studies confirms that high-intensity interval training (HIIT) improves glycemic control, cardiorespiratory fitness, and lipid profiles in type 2 diabetes patients, outperforming moderate-intensity exercise. Researchers highlight HIIT’s potential for diabetes management but call for further long-term studies.
Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway
March 21, 2025 / Rifaximin / MASH / Hepatic Fibrosis Treatment / Fibrosis Treatment / Metabolic Liver Disease
A study in MASH (metabolic dysfunction-associated steatohepatitis) mice shows rifaximin reduces liver fibrosis, inflammation, and transaminase levels by improving intestinal barrier integrity and downregulating the TLR4/NF-κB pathway, highlighting its therapeutic potential for MASH treatment.
New insights into T cell metabolism in liver cancer: from mechanism to therapy
March 23, 2025 / Liver Cancer Immunotherapy / T Cell Metabolism / Metabolic Reprogramming / Cancer Therapy
Liver cancer alters T cell metabolism, leading to immune dysfunction. Targeting T cell metabolic pathways with nanomaterials and drugs can enhance antitumor immunity. This review explores mechanisms, therapeutic strategies, and challenges in optimizing T cell metabolism for liver cancer treatment.
The association of nutritional and inflammatory status with cardiovascular and all-cause mortality risk among US patients with metabolic syndrome
March 20, 2025 / Cardiometabolic Syndrome / Inflammation Index / Cardiovascular Mortality / Nurition / Metabolic Disease Risk
A study using NHANES data identified the Advanced Lung Cancer Inflammation Index (ALI) as the most effective marker for assessing mortality risk in cardiometabolic syndrome (CMS). Proper nutritional and inflammatory balance correlates with reduced cardiovascular and all-cause mortality.
The Unexpected Effects of GLP-1 Medications on Women’s Health
March 19, 2025 / GLP-1 / Women’s Health / PCOS Treatment / Metabolic Regulation / Reproductive Health / Hormonal Balance
GLP-1 receptor agonists (GLP-1 RAs), originally developed for diabetes, offer broader benefits in women’s health, including metabolic regulation, hormone balance in PCOS, and potential cancer risk reduction. Their effects on reproductive health and pregnancy outcomes require further study.
Pecans found to improve cholesterol, diet quality and lower heart disease risk
March 18, 2024 / Pecans / Heart Health / Metabolic Syndrome Diet / Cardiovascular Health
A Penn State study found that replacing snacks with pecans improved cholesterol levels and diet quality in adults with metabolic syndrome risk factors. Pecans’ polyphenols and flavan-3-ols support cardiovascular health by reducing LDL cholesterol and enhancing vascular function.
Biomarkers identified by machine learning could assist in diagnosing liver diseases
March 20, 2024 / MASLD Biomarkers / Machine Learning / Liver Disease / Hepatic Fibrosis Diagnosis / AI / Liver Disease
A machine learning study identified key biomarkers, including HbA1c, BMI, triglycerides, and uric acid, to predict metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis. Predictive models showed high accuracy, potentially reducing reliance on liver biopsies.
Duke-NUS and NUS Medicine launch first-ever joint center to drive metabolomics research
March 22, 2024 / Metabolomics Research / Cardiometabolic Biomarkers
Duke-NUS and NUS Medicine launched the Systems Metabolomics Center (SysMeC) to advance metabolomics research, focusing on early disease detection and precision medicine. Initial projects target cardiometabolic diseases using mass spectrometry to analyze metabolic biomarkers like ceramides.